GERRESHEIMER

Q3

Interim Report

December 2008 – August 2009

Key Facts
Third quarter of 2009

- Group net sales of EUR 242.6m below prior year's quarter (-9.5 %), Group net sales excluding Technical Plastic Systems (sold as of July 1, 2009) -5.3 %
  - Pharma business continues to be robust
  - Cosmetics and Life Science Research show sales reduction as a result of the economic downturn
- Adjusted EBITDA margin steady at 17.3 % due to adjustments to the cost base
- Investments in growth projects proceeding according to plan
- Earnings per share of EUR -0.11 compared to EUR -0.73 in the prior year's quarter
- Adjusted earnings per share amount to EUR 0.20 after EUR 0.52 in Q3 2008

Group Key Figures (IFRS)

Financial Year end November 30	**Q3 2009**	Q3 2008	**Q1–Q3 2009**	Q1–Q3 2008	FY 2008
Results of Operations during the Reporting Period in EUR m					
Net sales	242.6	268.0	744.3	783.4	1,060.1
Adjusted EBITDA [1]	42.0	50.3	127.8	146.9	206.4
in % of net sales	17.3	18.8	17.2	18.8	19.5
Adjusted EBITA [2]	23.3	32.5	71.9	92.9	135.6
in % of net sales	9.6	12.1	9.7	11.9	12.8
Net income	-4.0	-22.8	-4.2	-14.7	4.5
Adjusted net income [3]	7.9	16.5	28.6	44.0	61.4
Net Assets as of the Reporting Date in EUR m					
Total assets	1,377.0	1,430.7	1,377.0	1,430.7	1,538.3
Equity	466.5	480.2	466.5	480.2	479.1
Equity ratio in %	33.9	33.6	33.9	33.6	31.1
Net working capital	180.8	205.9	180.8	205.9	163.0
in % of net sales during the preceding 12 months	17.7	19.7	17.7	19.7	15.4
Capital expenditure (cumulated)	19.1	20.2	50.3	54.4	107.8
Net financial debt	430.7	437.8	430.7	437.8	421.6
Adjusted EBITDA leverage [4]	2.3	2.1	2.3	2.1	2.0
Financial and Liquidity Position during the Reporting Period in EUR m					
Cash flow from operating activities	37.2	42.4	32.8	68.6	165.3
Cash flow from investing activities	-22.1	-20.5	-52.6	-84.3	-133.4
thereof cash paid for capital expenditure	-19.2	-19.6	-50.3	-50.7	-103.3
Free cash flow before financing activities	15.1	21.9	-19.8	-15.7	31.9
Employees					
Employees as of the Reporting Date (total)	9,431	10,298	9,431	10,298	10,177
Stock Data					
Number of shares as of the Reporting Date in million	31.4	31.4	31.4	31.4	31.4
Share price [5] as of the Reporting Date in EUR	19.66	34.41	19.66	34.41	27.10
Market capitalization as of the Reporting Date in EUR m	617.3	1,080.5	617.3	1,080.5	850.9
Share price high [5] during the Reporting Period in EUR	19.66	35.89	27.05	38.20	38.20
Share price low [5] during the Reporting Period in EUR	15.35	30.92	13.24	29.48	23.99
Earnings per share in EUR	-0.11	-0.73	-0.15	-0.53	0.02
Adjusted earnings per share [6] in EUR	0.20	0.52	0.83	1.34	1.83
Dividend per share in EUR	–	–	–	–	0.40

[1] Adjusted EBITDA: Earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses

[2] Adjusted EBITA: Earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, restructuring expenses and one-off income and expenses

[3] Adjusted net income: Consolidated profit before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects

[4] Adjusted EBITDA leverage: The relation of interest bearing net debt to adjusted EBITDA of the preceding 12 months

[5] In each case Xetra closing price

[6] Adjusted net income after minorities divided by 31.4m shares

Segment Key Figures

Tubular Glass

in EUR m	Q3 2009	Q3 2008	Q1–Q3 2009	Q1–Q3 2008	FY 2008
Net Sales [7]	74.1	77.6	225.0	221.3	302.0
Adjusted EBITDA [1]	17.6	19.1	53.2	54.2	77.3
in % of net sales	23.8	24.6	23.6	24.5	25.6
Capital expenditure (cumulated)	4.8	8.1	11.7	19.6	38.4

Plastic Systems

in EUR m	Q3 2009	Q3 2008	Q1–Q3 2009	Q1–Q3 2008	FY 2008
Net Sales [7]	74.8	87.8	238.4	258.6	346.0
thereof sales Technical Plastic Systems	5.7	17.8	29.4	56.0	74.2
Adjusted EBITDA [1]	16.5	15.4	47.5	47.4	66.7
in % of net sales	22.1	17.5	19.9	18.3	19.3
Capital expenditure (cumulated)	5.6	6.0	13.8	21.3	35.8

Moulded Glass

in EUR m	Q3 2009	Q3 2008	Q1–Q3 2009	Q1–Q3 2008	FY 2008
Net Sales [7]	74.8	83.7	224.9	246.9	333.7
Adjusted EBITDA [1]	11.0	17.4	35.4	52.0	71.1
in % of net sales	14.7	20.8	15.7	21.1	21.3
Capital expenditure (cumulated)	7.7	5.8	22.1	12.2	30.2

Life Science Research

in EUR m	Q3 2009	Q3 2008	Q1–Q3 2009	Q1–Q3 2008	FY 2008
Net Sales [7]	21.8	22.9	66.0	67.3	92.8
Adjusted EBITDA [1]	2.0	2.9	6.1	8.0	11.3
in % of net sales	9.2	12.7	9.2	11.9	12.2
Capital expenditure (cumulated)	0.9	0.2	2.5	1.0	3.0

Net sales [7] Q3 2009
by Segment

Tubular Glass
30 %

Plastic Systems
30 %

Moulded Glass
30 %

Life Science Research
10 %

Adjusted EBITDA [8] Q3 2009
by Segment

Tubular Glass
38 %

Plastic Systems
35 %

Moulded Glass
23 %

Life Science Research
4 %

Employees [9] as of August 31, 2009
by Segment

Tubular Glass
38 %

Plastic Systems
26 %

Moulded Glass
25 %

Life Science Research
11 %



[7] Net sales by segment include intercompany sales

[8] The total of the EBITDAs by segment does not include central functions

[9] The total number of employees by segment does not include central functions

Content

Gerresheimer AG Shares

Continued General Share Price Recovery

Notwithstanding the worldwide financial and economic crisis the general share price recovery which had begun in the second quarter continued also in the third quarter of the financial year 2009. Hopes of a forthcoming improvement of the economic situation and higher corporate earnings figures led to increased demand for shares and thereby drove up share prices respectively. Hence, MDAX und DAX managed to continue their upward movement which they had previously started also in the third quarter. Overall, the MDAX recorded a plus of 25.5 % in the first nine months of the financial year 2009 while the DAX gained 17.0 % over the same period. Gerresheimer shares also increased in value in the third quarter 2009 and closed with a plus of 20.5 %. In the first nine month period of the financial year 2009 the shares decreased by 27.5 % in value, after they had in part considerably outperformed the selection indices beforehand.

Further Increased Stock-Exchange Turnover of the Shares

The market capitalization of the Company amounted to EUR 617.3m at the end of the third quarter on August 31, 2009. According to the index system of the German Stock Exchange, Gerresheimer shares therefore occupied 32nd place in the MDAX ranking list (prior year's quarter: 27th position). In terms of stock-exchange turnover the shares were in 42nd place on the cut-off date, compared with a 63rd place at the end of the prior year's quarter. On average a total of 193,764 shares were traded each day in the third quarter 2009 (Q3 2009: 75,964 shares). Therefore the shares marked their historic high with regards to stock-exchange turnover since the IPO of Gerresheimer AG in June 2007.

Comparison of Gerresheimer AG Share Performance with MDAX and DAX



Key Data for the Shares	Q3 2009	Q3 2008	Q1–Q3 2009	Q1–Q3 2008	FY 2008
Number of shares as of the Reporting Date in million	31.4	31.4	31.4	31.4	31.4
Share price [1] as of the Reporting Date in EUR	19.66	34.41	19.66	34.41	27.10
Market capitalization as of the Reporting Date in EUR m	617.3	1,080.5	617.3	1,080.5	850.9
Share price high [1] during the Reporting Period in EUR	19.66	35.89	27.05	38.20	38.20
Share price low [1] during the Reporting Period in EUR	15.35	30.92	13.24	29.48	23.99
Earnings per share in EUR	-0.11	-0.73	-0.15	-0.53	0.02
Adjusted earnings per share [2] in EUR	0.20	0.52	0.83	1.34	1.83
Dividend per share in EUR	–	–	–	–	0.40

[1] In each case Xetra closing price
[2] Adjusted net income after minorities divided by 31.4m shares

Quarterly Group Management Report
December 2008 – August 2009

BUSINESS ENVIRONMENT

In the reporting period from December 2008 to August 2009 the worldwide macroeconomic situation eased slightly after the initially strong recession at the beginning of the year. Although the production level in the second quarter 2009 was still considerably below the prior year quarter's figures, the decline turned out to be less steep than at the beginning of the year. The stabilization of the financial markets, which was enabled to a considerable extent by interventions of central banks coupled with public restructuring programs and guarantees for the finance sector, contributed significantly to this slight improvement. Hereupon, investors' readiness to assume risk increased noticeably. In addition, the stimulating impact of governmental economic stimulus plans became increasingly visible.

While the economic performance decreased again in the second quarter 2009, the overall economic production level is estimated to have moved upward significantly in the third quarter 2009, according to the assessment of the Kiel Institute for the World Economy. For the third quarter 2009, experts expect an increase in US economic performance of about 2.9 % for the first time since the crisis began. For the Eurozone however, a fall in economic performance of about 4.2 % is continued to be forecast. With regards to the German economy analysts are even anticipating a decline in gross domestic product of about 5.3 % on average.

The market for pharmaceutical primary packaging demonstrated its robustness also during the course of the year 2009. The demographic change and the accompanying increased demand for medical care as well as the rising prevalence of acute and chronic diseases enable stable growth in demand. The same is true for other market determinants, for example the trend towards patients' selfmedication, which increasingly substitutes stationary and ambulatory care, and the increasing number of generics and biotech drugs.

As in the first half of 2009, some pharma companies continued to reduce their inventory levels also in the third quarter, owing to the economic conditions. This resulted in temporarily lower sales recorded by suppliers to pharma companies. Also, in the cosmetics industry lower sales were recorded due to the continued inventory reduction along with declining demand, particularly for high priced cosmetics.

BUSINESS DEVELOPMENT

In an extremely challenging market environment the Gerresheimer Group virtually maintained its sales level in the first three quarters of the financial year. Sales (excluding Technical Plastic Systems which was sold with effect from July 1) declined by a nominal 1.7 %. Ongoing inventory reductions on the part of some customers as well as the continued weaker demand for higher priced cosmetic products and labware glass negatively impacted growth. On the contrary however growth rates of primary pharmaceutical packaging product sales could be observed.

Adjustments to capacity and cost structures as a result of the sales reduction kept the adjusted EBITDA margin of 17.9 % on a solid level for the first three quarters of the financial year (without Technical Plastic Systems).

Exchange rate fluctuations or the development of commodity prices had little influence on the operating result of the Gerresheimer Group in the reporting period. The long term financing structure with secured interest rates as well as contractually agreed liquidity reserves also offered the Group a sound foundation in the first three quarters of 2009. Fluctuations in the US dollar/euro exchange rate essentially only led to translation effects, as sales invoiced in US dollar originate most exclusively from the North American production sites and a part of the Group's non-current debt is in the form of US dollar loans. Price fluctuations for raw materials and energy are substantially equalized by contractually agreed price escalation clauses, hedging transactions, productivity and price increases.

In furthering our focus on pharma & life science, the Technical Plastic Systems business was sold with effect from July 1, 2009. The sales of this business including the tools business, which was also sold, amounted to EUR 74.2m in the financial year 2008 and to EUR 29.4m in the seven months it was part of the Group in 2009 (comparative prior year period: EUR 56.0m). The purchase price including the debt taken over amounted to around EUR 12m.

SALES DEVELOPMENT

The Gerresheimer consolidated sales of EUR 242.6m in the third quarter 2009 were 9.5 % lower than the sales achieved in the comparative prior year quarter of EUR 268.0m. In the first three quarters total sales of EUR 744.3m could be generated compared to EUR 783.4m in the comparative prior year period (-5.0 %). The main reason for this decline is the considerable sales reduction of the Technical Plastic Systems business, which has been sold in the meantime. In addition the Technical Plastic Systems sales of Q3 2009 are included with only one month whereas the comparative prior year quarter includes sales of three months. To enable a better overview initially the sales development excluding Technical Plastic Systems will be outlined and commented.

If the consolidated sales are adjusted by the sales of the Technical Plastic Systems the sales in the first three quarters of 2009 of EUR 714.9m were slightly below the comparative prior year sales level by 1.7 %. In the third quarter 2009 sales of EUR 236.9m were 5.3 % behind those of the comparative prior year quarter of EUR 250.2m; on a like-for-like exchange rate this corresponds to a sales decrease of 6.6 %. This was primarily caused by the continued weak demand for products of the Cosmetics and Labware Glass businesses. However, also the customers of the Pharma business used the summer months to undertake further inventory reductions.

in EUR m	**Q3 2009**	Q3 2008	Change in %	**Q1–Q3 2009**	Q1–Q3 2008	Change in %
Sales						
Tubular Glass	74.1	77.6	-4.5	225.0	221.3	1.7
Plastic Systems	69.1	70.0	-1.3	209.0	202.6	3.2
Moulded Glass	74.8	83.7	-10.6	224.9	246.9	-8.9
Life Science Research	21.8	22.9	-4.8	66.0	67.3	-1.9
Sub-total	**239.8**	**254.2**	**-5.7**	**724.9**	**738.1**	**-1.8**
Intragroup sales	-2.9	-4.0	-27.5	-10.0	-10.7	-6.5
Sales core activities	**236.9**	**250.2**	**-5.3**	**714.9**	**727.4**	**-1.7**
Technical Plastic Systems	5.7	17.8	-68.0	29.4	56.0	-47.5
Total sales	**242.6**	**268.0**	**-9.5**	**744.3**	**783.4**	**-5.0**

Sales by the Tubular Glass division in the third quarter of 2009 totalled EUR 74.1m, and were thereby below sales of the comparative prior year quarter of EUR 77.6m by 4.5 % (on a like-for-like exchange rate basis -7.1 %). In the first three quarters of 2009 the Tubular Glass segment grew slightly by EUR 3.7m to EUR 225.0m. Sales growth of 1.7 % could therefore be achieved in the first three quarters of 2009 (on a like-for-like exchange rate -2.2 %). Ampules and vials sales in Europe and China continued to develop positively. However, in the third quarter the reduction in inventory levels of some large pharma companies continued as expected, which had a contrary effect. The third production facility which is needed for further growth in the RTF® syringe business is currently being validated by our customers.

In the third quarter 2009 sales by the Plastic Systems division were on the same level as the comparative prior year period. On a like-for-like exchange rate basis sales increased by 1.3 %. In the first three quarters of 2009 sales grew by EUR 6.4m to EUR 209.0m thereby achieving a plus of 3.2 % (on a like-for-like exchange rate basis 5.5 %). Sales growth could particularly be achieved in the areas for inhalers and pen systems. When analyzing the sales in the Plastic Systems segment one must consider that the negative balance arising from acquisitions and disposals made in the prior financial year are included here. The sales lost from the disposal of the Consumer Healthcare business and from the aluminium business were higher than the gains achieved through the acquisition of Gerresheimer Zaragoza and Gerresheimer São Paulo.

Our Moulded Glass division generated sales of EUR 74.8m in the third quarter 2009. This corresponds to a decline in sales of 10.6 % compared to the prior year period. On a like-for-like exchange rate basis the sales of this division decreased by 11.9 %. In the first nine months of the financial year 2009 sales declined by 8.9 % (on a like-for-like exchange rate basis 11.1 %) to EUR 224.9m. The main driver for this development besides reduction in inventory levels was the continued weak demand for higher priced cosmetic products.

Sales by the Life Science Research division of a nominal EUR 21.8m in the third quarter 2009 were only marginally lower than the sales in the comparative prior year quarter of EUR 22.9m, however decreased by 12.9 % on a like-for-like exchange rate basis. In the first three quarters of 2009 the nominal sales also remained on the same level as the comparative prior year period however decreased by 12.8 % on a like-for-like exchange rate basis. The reduction in inventory levels on the part of dealers and end customers as well as reduced demand for reuseable labware glass attributable to budget cut-backs in some laboratories are causing the temporary decline in the business development.

The sales by Technical Plastic Systems declined by 47.5 % from EUR 56.0m in the first three prior year quarters to EUR 29.4m in the current reporting period. This is attributable to the ongoing crisis in the automotive industry on the one hand and on the other hand attributable to the fact that only one month's worth of sales are included in the third quarter 2009. Therefore, the sales development is no longer comparable with the prior year quarter.

RESULTS OF OPERATIONS

In the third quarter of the current financial year the Gerresheimer Group generated an adjusted EBITDA of EUR 42.0m and an adjusted EBITDA of EUR 127.8m for the first three quarters of the current financial year. The decline compared to the respective prior year quarters is primarily attributable to reduction in sales. Due to considerable adjustments made to capacity and cost structures the adjusted EBITDA margin could be kept on a solid level of 17.6 % for the third quarter and 17.9 % for the first three quarters of the current financial year (in each case without Technical Plastic Systems).

in EUR m	Q3 2009	Q3 2008	Change in %	Q1–Q3 2009	Q1–Q3 2008	Change in %
Adjusted EBITDA						
Tubular Glass	17.6	19.1	-7.9	53.2	54.2	-1.8
Plastic Systems	16.1	15.4[1]	4.5	47.8	47.4[1]	0.8
Moulded Glass	11.0	17.4	-36.8	35.4	52.0	-31.9
Life Science Research	2.0	2.9	-31.0	6.1	8.0	-23.8
Sub-total	**46.7**	**54.8**	**-14.8**	**142.5**	**161.6**	**-11.8**
Central function/Consolidation	-5.1	-4.5	13.3	-14.4	-14.7	-2.0
Adjusted EBITDA core activities	**41.6**	**50.3**	**-17.3**	**128.1**	**146.9**	**-12.8**
Technical Plastic Systems	0.4	–[1]	–	-0.3	–[1]	–
Total Adjusted EBITDA	**42.0**	**50.3**	**-16.5**	**127.8**	**146.9**	**-13.0**

[1] The adjusted EBITDA of the Technical Plastic Systems business of the comparative prior year period is not available due to the fact that the divestment was carried out in the course of the financial year and is therefore included in the Plastic Systems segment

Adjusted EBITDA for the Tubular Glass division decreased by 7.9 % to EUR 17.6m in the third quarter and by 1.8 % to EUR 53.2m in the first three quarters of 2009 respectively. The EBITDA margin of 23.8 % in the third quarter 2009 and 23.6 % for the first three quarters of the financial year are on a high level.

The adjusted EBITDA for the Plastic Systems division increased by 4.5 % to EUR 16.1m in the third quarter compared to the prior year period. In the first three quarters of 2009 the adjusted EBITDA of EUR 47.8m is slightly above the prior year level. In the comparative prior year periods the positive income effects of the Technical Plastic Systems were included herein, which are shown separately in 2009. Adjusted by the effects of the Technical Plastic Systems the margin of the Plastic Systems segment increased from 20.1 % in the first quarter 2009 to 23.3 % in the third quarter 2009. The main driver for this positive development was primarily the strong sales growth in the area of Medical Plastic Systems in which high margins can be achieved.

In the Moulded Glass division adjusted EBITDA declined by EUR 6.4m in the third quarter 2009 compared to the third quarter 2008 and in the first three quarters of 2009 by EUR 16.6m compared to the first three quarters of 2008. The sales decrease in this division has led to a reduction in contribution margins. Furthermore, additional costs for the routine furnace overhaul, which has been completed successfully in the meantime, as well as the merger of two furnaces have also burdened the result. Capacity and cost adjustments, which had already been implemented, have been reinforced.

In the Life Science Research division adjusted EBITDA declined as a result of reduced sales by EUR 0.9m to EUR 2.0m in the third quarter 2009 and by EUR 1.9m to EUR 6.1m in the first three quarters of 2009 respectively. The capacity and cost adjustments implemented in the first two quarters were continued in the third quarter and especially affected the plants producing reusable labware glass.

Adjusted EBITDA for the Technical Plastic Systems business was marginally positive in the third quarter 2009 and at EUR -0.3m only slightly negative in the first three quarters of 2009.

The adjusted EBITDA of the third quarter includes the expected special circumstance that higher contributions of about EUR 1m had to be made to the pension insurance association by the German companies.

The following table shows the reconciliation of adjusted EBITDA to the consolidated result for the period.

in EUR m	Q3 2009	Q3 2008	Change	Q1–Q3 2009	Q1–Q3 2008	Change
Adjusted EBITDA	**42.0**	**50.3**	**-8.3**	**127.8**	**146.9**	**-19.1**
Restructuring expenses	0.3	1.1	-0.8	1.8	2.3	-0.5
Exceptional income/expense [1]	0.6	-1.3	1.9	2.3	1.7	0.6
EBITDA	**41.1**	**50.5**	**-9.4**	**123.7**	**142.9**	**-19.2**
Fair value amortization [2]	9.5	10.7	-1.2	28.6	28.8	-0.2
Depreciation	18.7	17.8	0.9	55.9	54.0	1.9
Impairment loss	0.0	33.0	-33.0	5.3	37.6	-32.3
Profit from operations	**12.9**	**-11.0**	**23.9**	**33.9**	**22.5**	**11.4**
Finance costs -net [3]	-9.9	-10.1	0.2	-30.6	-30.4	-0.2
Income taxes	-7.0	-1.8	-5.2	-7.4	-6.8	-0.6
Consolidated profit for the period	**-4.0**	**-22.9**	**18.9**	**-4.1**	**-14.7**	**10.6**
Minority interests	-0.5	0.1	-0.6	0.5	2.0	-1.5
Profit attributable to equity holders of the parent	**-3.5**	**-23.0**	**19.5**	**-4.6**	**-16.7**	**12.1**
Adjusted Net Income	**7.9**	**16.5**	**-8.6**	**28.6**	**44.0**	**-15.4**

[1] The item "Exceptional income/expense" comprises one-off items which cannot be taken as an indicator of ongoing business operations. These include, for example, various expenses for reorganization and structure changes which are not reportable as "restructuring expenses" according to IFRS

[2] Amortization of fair value adjustments relates to the assets identified at fair value in connection with the acquisitions of Gerresheimer Group GmbH by Blackstone in December 2004, Gerresheimer Vaerlose in December 2005, Gerresheimer Wilden in January 2007, the pharma glass business of Comar Inc. in March 2007, USA, the new formation of the Kimble Chase joint venture in July 2007 as well as the acquisitions of Gerresheimer Zaragoza and Gerresheimer São Paulo in January 2008

[3] Finance costs (net) comprise interest income and expenses in relation to the net financial debt of the Gerresheimer Group. In addition, interest expenses for pension provisions less expected income from fund assets are included

Starting from adjusted EBITDA the restructuring expenses and exceptional income/expense reconcile to EBITDA. Profit from operations has improved considerably compared to the prior year periods. With a lower EBITDA and slightly higher depreciation the impairment losses from disinvestments have declined considerably.

The finance costs are on the same level as the prior year both from the point of view of the quarter and for the first nine month period. Income taxes of the third quarter 2009 include one-off tax effects from prior periods. After considering the result attributable to minority interests a loss attributable to the equity holders of the parent of EUR 4.6m and adjusted net income of EUR 28.6m arises for the first three quarters of 2009.

NET ASSETS

Assets	August 31, 2009 in EUR m	in %	Nov. 30, 2008 in EUR m	in %
Non-current assets	1,035.4	75.2	1,081.2	70.3
Current assets	341.6	24.8	457.1	29.7
Balance sheet total	**1,377.0**	**100.0**	**1,538.3**	**100.0**
Equity and Liabilities				
Equity and minority interests	466.5	33.9	479.1	31.1
Non-current liabilities	570.5	41.4	642.8	41.8
Current liabilities	340.0	24.7	416.4	27.1
Balance sheet total	**1,377.0**	**100.0**	**1,538.3**	**100.0**
Net financial debt	**430.7**	**31.3**	**421.6**	**27.4**
Net working capital	**180.8**	**13.1**	**163.0**	**10.6**

Compared to November 30, 2008, the balance sheet total of the Gerresheimer Group has decreased by EUR 161.3m to EUR 1,377.0m at August 31, 2009.

Non-current assets have declined by EUR 45.8m to EUR 1,035.4m in absolute terms; however in relation to the balance sheet total they have increased from 70.3 % to 75.2 %. The reduction is attributable to normal depreciation as well as to the fair value amortization which were higher than the investments made in the reporting period.

The reduction in current assets from EUR 457.1m to EUR 341.6m reflects the reduction in cash and cash equivalents on the one hand which was used in the first quarter 2009 to pay investments made in 2008 as well as to pay the dividend to the shareholders in April 2009. On the other hand the reduction is attributable to the derecognition of the Technical Plastic Systems business which was sold with effect from July 1, 2009.

Consolidated equity of the Gerresheimer Group including minority interests has declined to EUR 466.5m at August 31, 2009 which is mainly attributable to the dividend payment of EUR 12.6m being made. The equity ratio has increased from 31.1 % to 33.9 %.

The non-current liabilities of EUR 570.5m at the end of August 2009 have declined from EUR 642.8m at the end of November 2008 by EUR 72.3m. In that the non-current assets are to 100 % covered by equity and non-current assets (November 30, 2008: 104 %).

Current liabilities have declined from EUR 416.4 to EUR 340.0m which is primarily attributable to a reduction in liabilities in connection with investments made in the prior financial year as well as to the disposal of the Technical Plastic Systems.

The structure of the **net financial debt** of Gerresheimer AG is shown in the following table:

in EUR m	August 31, 2009	Nov. 30, 2008
Financial debt		
Senior facilities		
Term Loan [1]	209.6	256.4
Revolving Credit Facility [1]	75.1	53.8
Total senior facilities	**284.7**	**310.2**
Senior Notes	126.0	126.0
Local borrowings [1]	47.3	53.4
Capitalized lease obligations [2]	17.6	27.1
Total financial debt	**475.6**	**516.7**
Cash and cash equivalents [2]	44.9	95.1
Net financial debt	**430.7**	**421.6**
Adjusted LTM EBITDA [3]	**187.3**	**206.4**
Adjusted EBITDA leverage	**2.3**	**2.0**

1) For translation of US dollar loans to euros the following exchange rates were used: as at November 30, 2008: EUR 1.00/USD 1.2727; as at August 31,2009: EUR 1.00/USD 1.4272

2) Relates to prior period: Included herein are EUR 0.7m cash and cash equivalents as well as capitalized lease obligations of the disposal group

3) Cumulated adjusted EBITDA of the last 12 months

At August 31, 2009 Gerresheimer reports net financial debt of EUR 430.7m (November 30, 2008: EUR 421.6m). Besides seasonal fluctuations in net working capital the increase is primarily attributable to investments made in 2008, which were partly paid for in 2009, as well as to the dividend payment. Compared to the second quarter 2009 net financial debt has decreased by EUR 20.4m. The adjusted EBITDA leverage (the ratio of interest bearing net debt to adjusted EBITDA of the last twelve months) has increased from 2.0 at November 30, 2008 to 2.3 at August 31, 2009.

In June 2007 Gerresheimer concluded a new agreement on Credit Facilities totalling EUR 450m with a minimum term of five years with Commerzbank Aktiengesellschaft and The Royal Bank of Scotland plc as the facility agents. The new Credit Facilities comprise a long Term Loan totalling EUR 275.0m and a long term Revolving Loan of EUR 175.0m. The new credit facilities may be drawn either in euro, US dollars and further foreign currencies. In May 2008 Gerresheimer obtained an extension of one year for EUR 412m of the Senior Credit Facilities with terms and conditions unchanged. Therefore, the remaining term to maturity for the majority of the bank loans is four years.

At August 31, 2009 EUR 75.1m of the Revolving Credit of EUR 175.0m had been drawn. The remainder is available to Gerresheimer to finance investments and acquisitions and for other operating purposes.

The bond of EUR 126.0m issued in Luxembourg is due for repayment in the year 2015.

Net working capital (inventories plus trade receivables and prepayments less trade payables and payments received on account) for the Gerresheimer Group increased in the reporting period by EUR 17.8m to EUR 180.8m as at August 31, 2009 compared to November 30, 2008 (EUR 163.0m). Payments of investments made in 2008 in connection with seasonal fluctuations in the individual quarters, have contributed to the absolute increase in net working capital. Based on the sales of the past 12 months, net working capital has reduced from 19.7 % to 17.7 % compared to the comparative prior year quarter.

CASH FLOW STATEMENT
(Abbreviated version)

in EUR m	**Dec. 1, 2008– August 31, 2009**	Dec. 1, 2007– August 31, 2008
Cash flow from operating activities	32.8	68.6
Cash flow from investing activities	-52.6	-84.3
Cash flow from financing activities	-27.3	-28.8
Changes in cash and cash equivalents	-47.1	-44.5
Exchange rate related change in cash and cash equivalents	-3.1	0.2
Change in cash and cash equivalents of the disposal group	0.7	0.0
Cash and cash equivalents at the beginning of the period	94.4	80.3
Cash and cash equivalents at the end of the period	44.9	36.0

The cash inflow from operating activities in the first nine months of 2009 amounted to EUR 32.8m (prior year period: cash inflow of EUR 68.6m). In the first quarter especially liabilities had to be paid in connection with investments made in the financial year 2008. In the third quarter 2009 a cash inflow from operating activities of EUR 37.2m could be generated.

The net cash outflow from investing activities totalled EUR 52.6m, which is well below the prior year level of EUR 84.3m. The prior year figure comprised the acquisition of Gerresheimer Zaragoza and Gerresheimer São Paulo, which accounted for the majority of investments made besides investments in tangible assets.

The net cash flow from financing activities totalled EUR 27.3m. These funds were employed in particular for the payment of the dividend to the shareholders as well as for the repayment of loans.

CAPITAL EXPENDITURE

in EUR m	**Q3 2009**	Q3 2008	Change	**Q1–Q3 2009**	Q1–Q3 2008	Change
Tubular Glass	4.8	8.1	-3.3	11.7	19.6	-7.9
Plastic Systems	5.6	6.0	-0.4	13.8	21.3	-7.5
Moulded Glass	7.7	5.8	1.9	22.1	12.2	9.9
Life Science Research	0.9	0.2	0.7	2.5	1.0	1.5
Central	0.1	0.1	0.0	0.2	0.3	-0.1
Total capital expenditure	**19.1**	**20.2**	**-1.1**	**50.3**	**54.4**	**-4.1**

In the third quarter 2009 the Gerresheimer Group invested EUR 19.1m (comparative prior year quarter: EUR 20.2m). In the first nine months of 2009 investments in tangible assets of EUR 50.3m (prior year period: EUR 54.4m) were made. The main focus continued to be on capacity expansions aimed at achieving further growth. Namely, for the Tubular Glass division investments in the third production facility for RTF® syringes and the construction of a new production facility in China; for the Plastic Systems segment investments were made for the development of the production of pen systems, a new research and development center for Medical Plastic Systems, a new plant in Masalavés in Spain (region of Valencia) for standardized pharmaceutical systems as well as for the expansion of clean rooms. In addition investments in the segment Moulded Glass have been made in connection with routine furnace overhauls as well as for the merging of two furnaces.

For the financial year 2009 an investment volume of EUR 85m to EUR 90m is expected. Cut-backs were made to capacity expansions planned in areas, which are currently not fully utilized due to decreased sales.

EMPLOYEES

As at August 31, 2009 the Gerresheimer Group employed 9,431 people. Compared to November 30, 2008 the number of employees has decreased by 746. The reduction is both attributable to the sale of the Technical Plastic Systems business as well as to adjustments to the personnel structure. Furthermore, in order to adjust employment levels to the reduced demand the possibility of short-time work is especially being used at locations with cosmetic products and in the Life Science Research division.

Employees by Region
(Total number: 9,431)



At August 31, 2009 the Gerresheimer Group, employed 5,144 people in Europe (including 3,239 in Germany), 2,904 in Americas (including Mexico, Brazil and Argentina) and 1,383 in China.

REPORT ON RISKS AND OPPORTUNITIES

Gerresheimer continues to focus on growth in the core segment of pharmaceutical primary packaging. Global economic trends, exchange rate factors, rising material and energy prices and uncertainties about the future development of national healthcare systems represent risks which may affect the course of business in the long term. We are conscious of these risks and carry out regular reviews.

Even though the world economy recovered slightly in the third quarter, experts continue to anticipate a shrinking of the total economic performance. A fundamental recovery of the economy is not expected until the middle/end of 2010.

Currently, no risks which could threaten the Gerresheimer Group´s existence are identifiable.

OUTLOOK – ECONOMIC ENVIRONMENT

The following statements on the Gerresheimer Group's future business performance and the assumptions made as regards the economic development of our markets deemed to be significant in this respect are based on our assessments which we believe are realistic in accordance with the information currently available to us. However, these assessments entail uncertainty and present the unavoidable risk that the developments may not actually occur either in line with the tendency or the degree to which they were forecast.

After the strong decline in the worldwide economic performance which was caused by the dramatic culmination of the financial market crisis in Autumn 2008, world economic output contracted again markedly in the second quarter 2009. The economic downswing continued in the industrialized countries as well as in the emerging markets.

The recession manifests itself markedly in the projections of the economic development in 2009. However, the estimations were slightly revised upward for the first time during the course of the third quarter 2009. Thus financial analysts and economic experts forecast a decline of about 2.6 % in the USA (June 2009 forecast: -2.7 %) and a decline of about 4.0 % in Europe (June 2009 forecast: -4.2 %). Especially in Germany the forecast was revised upward slightly. The expected decline in real gross domestic product of 5.1 % turned out to be less significant than had been previously assumed in June (-6.0 %). Even if the German economy is slowly regaining momentum, according to the estimation by the Kiel Institute for the World Economy, the forecast turns out to be very significantly negative, compared to the second strongest German recession, which dates back to the year 1975 which showed a decline of 0.9 %.

OUTLOOK – FUTURE BUSINESS PERFORMANCE

Despite uncertainties in connection with the ongoing economic development of the global economy, volatile commodity and energy prices and an increase in exchange rate volatility, we continue to expect a stable business development in the pharma business. We incurred a considerable decline in demand in the more cyclical Cosmetics and Life Science Research businesses in the first nine months of the financial year. For the fourth quarter a slight recovery for Cosmetics is beginning to show, whereas we do not expect a recovery for the Life Science Research segment in the fourth quarter.

At present, no one can say with absolute certainty how the financial crisis will impact the real economy and therefore the Group's suppliers and customers. Consequently, forecasts entail an ever greater degree of uncertainty. One-off effects in particular due to a relatively high number of product launches, general overhauls of furnaces and incalculability relating to the order pattern of our customers will lead to a temporary decline in the adjusted EBITDA margin compared to 2008. As a consequence of the introduced cost containment measures we expect that the operating result will remain on a high level.

Our sound balance sheet and long term financing structure as well as our good operating performance will, from today's perspective, enable us to continue our growth strategy in the pharma & life science segment going forward.

Quarterly Consolidated Financial Statements according to IFRS
December 2008 – August 2009

CONSOLIDATED INCOME STATEMENT (IFRS)
for the Period from December 1, 2008 to August 31, 2009

in EUR k	Note	June 1, 09– August 31, 09	June 1, 08– August 31, 08	Dec. 1, 08– August 31, 09	Dec. 1, 07– August 31, 08
Sales		242,579	268,049	744,268	783,446
Cost of sales [1]		-182,486	-196,269	-552,629	-567,832
Gross profit [1]		**60,093**	**71,780**	**191,639**	**215,614**
Selling expenses [1]		-28,719	-34,056	-91,064	-99,060
General administrative expenses		-18,213	-16,347	-56,029	-56,123
Other operating income		5,067	3,893	14,780	13,208
Restructuring expenses	(4)	-330	-1,069	-1,855	-2,266
Other operating expenses		-4,979	-35,229	-23,631	-49,041
Share of results of associated companies		-44	108	39	211
Result from ordinary activities		**12,875**	**-10,920**	**33,879**	**22,543**
Financial income		224	209	983	861
Financial expenses		-10,124	-10,313	-31,582	-31,303
		-9,900	-10,104	-30,599	-30,442
Consolidated profit before income taxes		**2,975**	-21,024	**3,280**	**-7,899**
Income taxes	(7)	-7,022	-1,812	-7,466	-6,812
Consolidated profit for the period		**-4,047**	**-22,836**	**-4,186**	**-14,711**
Attributable to minority interests		-502	183	502	2,045
Attributable to equity holders of the parent		-3,545	-23,019	-4,688	-16,756
Earnings per share (in euro) [2]		**-0.11**	**-0.73**	**-0.15**	**-0.53**

[1] The functional costs include amortization of fair value adjustments. The prior year figures were adjusted accordingly, see Note (5)

[2] The earnings per share figure stated here also corresponds to the diluted EPS as no further shares have been issued

Notes (1) to (13) are an integral part of these consolidated quarterly financial statements

CONSOLIDATED BALANCE SHEET (IFRS)
as of August 31, 2009

ASSETS in EUR k	August 31, 2009	Nov. 30, 2008
Non-current assets		
Intangible assets	509,331	538,452
Property, plant and equipment	456,314	481,820
Investment property	3,545	3,545
Financial Assets	3,337	3,337
Investments accounted for using the equity method	3,211	3,606
Other financial assets	15,718	6,310
Deferred tax assets	43,933	44,179
	1,035,389	**1,081,249**
Current assets		
Inventories	149,304	154,063
Trade receivables	126,456	142,983
Income tax receivables	1,988	1,927
Other financial assets	171	11,299
Other receivables	18,811	21,262
Cash and cash equivalents	44,888	94,368
Assets and disposal group held for sale	0	31,130
	341,618	**457,032**
Total assets	**1,377,007**	**1,538,281**

EQUITY AND LIABILITIES in EUR k	August 31, 2009	Nov. 30, 2008
Equity		
Subscribed capital	31,400	31,400
Capital reserve	513,827	513,827
Cash flow hedge reserve	-6,086	-8,233
Currency translation reserve	12,089	3,114
Retained earnings	-123,232	-105,984
Equity attributable to equity holders of the parent	**427,998**	**434,124**
Minority interests	38,532	44,968
	466,530	**479,092**
Non-current liabilities		
Deferred tax liabilities	79,050	79,833
Provisions for pensions and similar obligations	140,008	145,251
Other provisions	6,720	7,464
Financial liabilities	344,708	410,202
	570,486	**642,750**
Current liabilities		
Provisions for pensions and similar obligations	14,606	15,153
Other provisions	45,995	53,965
Trade payables	83,242	137,858
Financial liabilities	142,278	122,508
Income tax liabilities	4,794	15,131
Other liabilities	49,076	55,253
Liabilities directly associated with assets and disposal group held for sale	0	16,571
	339,991	**416,439**
	910,477	**1,059,189**
Total equity and liabilities	**1,377,007**	**1,538,281**

Notes (1) to (13) are an integral part of these quarterly financial statements

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (IFRS)
from December 1, 2008 to August 31, 2009

in EUR k	Subscribed Capital	Capital Reserve	Cash flow hedge reserve
As of December 1, 2007	**31,400**	**513,827**	**-4,245**
Change in the consolidated group	–	–	–
Capital contribution by minorities	–	–	–
Changes in the fair value of interest rate swaps	–	–	-757
Fair value of interest rate swaps recognized in profit or loss	–	–	532
Currency translation differences	–	–	-34
Total profit or loss recognized directly in equity	**–**	**–**	**-259**
Result	–	–	–
Total result	**–**	**–**	**-259**
Distribution	–	–	–
As of August 31, 2008	**31,400**	**513,827**	**-4,504**
As of December 1, 2008	**31,400**	**513,827**	**-8,233**
Changes in fair values of interest rate swaps	–	–	4,686
Fair value of interest rate swaps recognized in profit or loss	–	–	-3,242
Currency translation differences	–	–	703
Total profit or loss recognized directly in equity	**–**	**–**	**2,147**
Result	–	–	–
Total result	**–**	**–**	**2,147**
Distribution	–	–	–
As of August 31, 2009	**31,400**	**513,827**	**-6,086**

Notes (1) to (13) are an integral part of these quarterly financial statements

Currency translation differences	Retained earnings	Total retained earnings	Equity holders of the parent	Minority interest	Total equity
18,539	**-94,157**	**-75,618**	**465,364**	**34,495**	**499,859**
–	–	–	–	37	37
–	–	–	–	1,484	1,484
–	–	–	-757	–	-757
–	–	–	532	–	532
7,599	–	7,599	7,565	666	8,231
7,599	**–**	**7,599**	**7,340**	**666**	**8,006**
–	-16,756	-16,756	-16,756	2,045	-14,711
7,599	**-16,756**	**-9,157**	**-9,416**	**2,711**	**-6,705**
–	-12,560	-12,560	-12,560	-1,877	-14,437
26,138	**-123,473**	**-97,335**	**443,388**	**36,850**	**480,238**
3,114	**-105,984**	**-102,870**	**434,124**	**44,968**	**479,092**
–	–	–	4,686	–	4,686
–	–	–	-3,242	–	-3,242
8,975	–	8,975	9,678	-5,312	4,366
8,975	**–**	**8,975**	**11,122**	**-5,312**	**5,810**
–	-4,688	-4,688	-4,688	502	-4,186
8,975	**-4,688**	**4,287**	**6,434**	**-4,810**	**1,624**
–	-12,560	-12,560	-12,560	-1,626	-14,186
12,089	**-123,232**	**-111,143**	**427,998**	**38,532**	**466,530**

CONSOLIDATED CASH FLOW STATEMENT (IFRS)
for the Period from December 1, 2008 to August 31, 2009

in EUR k	Dec. 1, 2008– August 31, 2009	Dec. 1, 2007– August 31, 2008
Consolidated profit/loss for the period	-4,186	-14,711
Income taxes	7,466	6,812
Depreciation of property, plant and equipment	57,731	55,575
Amortization of intangible assets	26,738	27,177
Impairment loss	5,277	37,609
Change in valuation of equity-accounted investments	-39	-211
Change in provisions	-7,048	786
Change in provisions for pensions and similar obligations	-9,253	-9,562
Gain/loss on the disposal of non-current assets	-151	-2,827
Financial result	30,599	30,442
Interest paid	-29,323	-24,891
Interest received	850	640
Income taxes paid	-19,380	-3,729
Income taxes received	1,065	840
Change in net working capital:		
Change in inventories	-38	-24,960
Change in trade receivables and other assets	17,217	408
Change in trade payables and other liabilities	-58,839	-11,415
Other non-cash expenses/income	14,097	629
Cash flow from operating activities	**32,783**	**68,612**
Cash received from disposals of non-current assets	596	3,506
Cash paid for investments:		
in property, plant and equipment	-49,896	-48,575
in intangible assets	-421	-2,136
in financial assets	-	-
Cash paid out in connection with disinvestment	-2,863	-
Cash paid out for the acquisition of subsidiaries, net of cash received	-	-37,089
Cash flow from investing activities	**-52,584**	**-84,294**

in EUR k	**Dec. 1, 2008–August 31, 2009**	Dec. 1, 2007–August 31, 2008
Distributions to third parties	-14,186	-14,437
Contributions made by minority shareholders	-	1,484
Raising of loans	32,705	51,724
Repayment of loans	-39,935	-62,843
Repayment of finance lease liabilities	-5,904	-4,770
Cash flow from financing activities	**-27,320**	**-28,842**
Changes in cash and cash equivalents	**-47,121**	**-44,524**
Change in cash and cash equivalents of the disposal group	748	-
Exchange rate related change in cash and cash equivalents	-3,107	238
Cash and cash equivalents at the beginning of the period	94,368	80,266
Cash and cash equivalents at the end of the period	**44,888**	**35,980**

Notes (1) to (13) are an integral part of these quarterly financial statements

NOTES TO THE QUARTERLY CONSOLIDATED FINANCIAL STATEMENTS
of Gerresheimer AG for the period from December 1, 2008 to August 31, 2009

(1) Reporting principles

The Gerresheimer Group based in Düsseldorf (Germany) comprises Gerresheimer AG and its direct and indirect subsidiaries.

The present quarterly Consolidated Financial Statements were drawn up in accordance with the International Financial Reporting Standards (IFRS) by the International Accounting Standards Board (IASB) in so far as they should be applied in the EU (section 315a of the German Commercial Code (HGB)), and in accordance with IAS 34 "Interim Financial Reporting". These notes to the quarterly consolidated financial statements therefore do not contain all the information and details required by IFRS for Consolidated Financial Statements at the end of a financial year, and should be read in conjunction with the consolidated financial statements as at November 30, 2008. The present financial statements have not been audited.

The income statement was drawn up using the function of expense method. Restructuring expenses are shown separately because of their significance. The same accounting principles generally apply as in the annual financial statements for 2008. For the consolidated financial statements as at August 31, 2009 the advice given by RIC (Accounting Interpretations Committee of the Accounting Standards Committee of Germany (DRSC)) regarding the consideration of the expected increase in the compulsory contributions to the pension insurance association was met by setting up a provision.

The following interpretations were applied for the first time:

- IFRIC 12, Service Concessions Arrangements
- IFRIC 13, Customer Loyalty Programmes

The adoption of these amended pronouncements has no effect on the Group's net assets, financial position and results of operation.

In preparing the quarterly Consolidated Financial Statements in accordance with prevailing accounting principles, estimates and assumptions are made which have an effect on the valuation of assets and liabilities, the disclosure of contingent liabilities and assets as of the balance sheet date as well as on the amount of income and expenses in the reporting period. Although the estimates are made to the best of management's knowledge of current events and transactions, the actual future results may differ from the estimates.

The consolidated financial statements are in euros, the functional currency of the parent company. Conversion of the major currencies in the Group was based on the following exchange rates:

	Closing rate for EUR as of		Average rate for EUR as of	
Currency	**August 31, 2009**	Nov. 30, 2008	**Dec. 1, 2008 – August 31, 2009**	Dec. 1, 2007– August 31, 2008
1 BRL	0.3692	0.3366	0.3430	0.3915
1 CZK	0.0394	0.0397	0.0377	0.0396
1 DKK	0.1344	0.1342	0.1343	0.1341
1 GBP	1.1346	1.2050	1.1260	1.2953
1 MXN	0.0526	0.0591	0.0539	0.0623
1 PLN	0.2437	0.2649	0.2306	0.2888
1 RMB	0.1026	0.1150	0.1080	0.0931
1 USD	0.7007	0.7857	0.7380	0.6559

The Consolidated Financial Statements of Gerresheimer AG as at November 30, 2008 are published in the online edition of the electronic Federal Law Gazette (elektronischer Bundesanzeiger) in the German language and on the Internet at www.gerresheimer.com.

(2) Seasonal effects on business activity

The business is subject to seasonal influences, as sales in Europe and North America are usually lowest in the holiday period in December/January and during the summer months.

(3) Changes in the group of consolidated companies

Sale of the Technical Plastics Business

The Gerresheimer Group sold the Technical Plastics Systems business (TPS) on July 1, 2009. The business, which primarily manufactures plastic system components for suppliers to the automotive industry, was not part of the core business of the Gerresheimer Group and fell short of meeting the margin expectations of Gerresheimer. The sales process was started through an international invitation for bids on August 1, 2008. In accordance with IFRS 5 the income and expenses generated to the date of disposal are included in the result of continued operations. At November 30, 2008 the assets and liabilities were shown separately in the balance sheet in the lines “Assets and disposal group held for sale” and “Liabilities directly associated with assets and disposal group held for sale”. Assets held for sale, disposal groups as well as the directly associated liabilities were valued at fair values less selling costs in accordance with IFRS 5. The accounting loss of EUR 5.3 m resulting from the sale is included in the income statement as an impairment loss within other operating expenses in the Plastic Systems segment.

Notes to the abbreviated Quarterly Consolidated Financial Statements

(4) Restructuring expenses

Restructuring expenses are shown separately because of their significance. In the reporting period as in the comparable prior year period, restructuring expenses relate mainly to measures to cut costs and increase efficiency in production, marketing and administration in various subsidiaries of the Gerresheimer Group. The restructuring expenses comprise personnel expenses of EUR 1.4m (comparative prior year quarter: EUR 1.7m).

(5) Amortization of fair value adjustments

The following table shows the fair value adjustments resulting from the acquisitions of Gerresheimer Group GmbH in 2004 through a company controlled by Blackstone, Gerresheimer Vaerloese at the end of December 2005, Gerresheimer Wilden at the start of January 2007, the pharma glass business of Comar Inc. in March 2007, the formation of the Kimble Chase joint venture in July 2007 and the acquisitions of Gerresheimer Zaragoza and Gerresheimer São Paulo at the end of January 2008.

in EUR m	Fair value adjustments Carrying value as of August 31, 2009	**Amortization of fair value adjustments Q1–Q3 2009**	Amortization of fair value adjustments Q1–Q3 2008
Customer base	88.1	20.3	21.0
Orders on hand	0.0	0.0	0.2
Brand names	28.1	0.0	0.0
Technologies	12.0	2.5	2.2
Process know-how	1.0	2.7	2.6
Land	4.2	0.0	0.0
Buildings	12.0	0.4	0.3
Machinery	7.5	2.7	2.5
	152.9	**28.6**	**28.8**

The amortization of the fair value adjustments is disclosed in the functional areas and no longer as a separate item in the income statement as in the prior quarters. Of the total EUR 28.8m fair value amortization in the prior year nine month period, EUR 7.6m relate to cost of sales and EUR 21.2m to selling expenses. The values of the comparative prior year period have been adjusted accordingly. Of the EUR 28.6m fair value amortization of the current nine month period EUR 8.3m relate to cost of sales and EUR 20.3m to selling expenses.

The brand names contained in the above table were identified as intangible assets with an indefinite useful economic life. Brand names are therefore no longer amortized on a straight line basis but are subjected to an impairment test at least once a year in accordance with IFRS 3 “Business Combinations” and the revised IAS 36 “Impairment of Assets” and IAS 38 “Intangible Assets”.

(6) Gerresheimer stock appreciation rights (phantom stocks)

A share-based remuneration system and virtual shares were introduced in the financial year 2007. Details of the phantom stock program can be found in the notes to the consolidated financial statements as at November 30, 2008.

On July 5, 2008 and July 13, 2009 further tranches of phantom stocks were granted. The terms and conditions for these new tranches are identical to those of the first tranche given in 2007.

For determining the fair value of the phantom stocks a recognized option price model (binomial model) was used. The volatility of the target value in the first nine months of 2009 was set at 55.5 % p.a. and the employee fluctuation rate set at 8 %. As a risk-free interest rate the yield on Federal German bonds of 1.25 % p.a. was taken.

	Tranche 1	Tranche 2	Tranche 3
Grant date	June 11, 2007	July 5, 2008/ June 11, 2007	July 13, 2009/ May 1, 2009/ June 11, 2007
Term of tranche	October 31, 2009	October 31, 2010	October 31, 2011
End of vesting period	July 4, 2008	June 16, 2009	June 15, 2010
Issue price (in EUR)	40.00	34.40	17.48
Target price (in EUR)	43.20	37.15	18.88
Number of stock appreciation rights issued	520,000	524,500	710,500
Exercise threshold (in %)	8.0	8.0	8.0
Fair value (in EUR k)	0	188	1,105
Maximum pay-out amount (in EUR k)	5,200	4,511	3,105

In addition to the tranches referred to above, in the years 2007 and 2009 the board members and a few further employees were granted additional tranches for the years 2010 – 2014. Based on the above assumptions, the fair value of the 2010 – 2014 tranches is EUR 1,014k at the balance sheet date.

(7) Income tax expenses

The main components of income tax reported in the abbreviated consolidated income statement are as follows:

in EUR k	Q1–Q3 2009	Q1–Q3 2008
Current income tax (expense (-)/income)	-8,239	-11,982
Deferred income tax (expense (-)/income)	773	5,170
	-7,466	**-6,812**

(8) Dividend paid/Distributions to third parties

In the Annual General Meeting on April 29, 2009 a resolution was passed to pay a dividend of EUR 0.40 per share. This corresponds to a total dividend distribution of EUR 12.6m.

The dividends to minority shareholders of EUR 2.9m (including a guaranteed dividend which was recorded as a liability in 2007) were made to Chase Scientific Glass Inc., USA, which has a 49 % shareholding in the joint venture Kimble Chase Life Science and Research Products LLC. A further EUR 0.2m was distributed to the minority shareholder Zhenjiang Shuangfeng Glass Co. Ltd., which has a 40 % shareholding in the Shuangfeng joint venture.

In the prior year period a distribution of EUR 2.9m was made. Of that EUR 2.6m related to Chase Scientific Glass Inc., USA. A further EUR 0.3m was distributed to the minority shareholder Zhenjiang Shuangfeng Glass Co. Ltd.

(9) Financial liabilities

In June 2007 Gerresheimer entered into a new agreement for credit facilities totalling EUR 450m with Commerzbank Aktiengesellschaft and The Royal Bank of Scotland plc as the facility agents. The new Senior Facilities comprise a Term Loan of EUR 275.0m and a Revolving Credit Facility of EUR 175.0m. The facilities initially had terms up to June 2012 and are secured by a pledge of the shares in Gerresheimer Group GmbH. In May 2008 Gerresheimer obtained an extension of one year for EUR 412m of the Credit Facility. Therefore, the term for this part of the Credit Facility is now June 2013. The Revolving Credit of EUR 175.0m is available, for example, to finance investments and acquisitions and for other operating purposes. A total of EUR 75.1m had been drawn at August 31, 2009.

The bond of EUR 126.0m issued in Luxembourg is due for repayment in the year 2015.

(10) Other financial commitments

Commitments under rental and operating lease agreements as well as from capital expenditure commitments amount to EUR 25.9m at August 31, 2009 and have decreased by EUR 3.3m compared to November 30, 2008 which is mainly attributable to lower capital expenditure commitments in connection with routine furnace repairs as well as for the merging of two furnaces.

(11) Segment report

The Gerresheimer Group comprises the four divisions of Tubular Glass, Plastic Systems, Moulded Glass and Life Science Research. Segment reporting is in line with the Company's strategic focus.

By division in EUR m		Tubular Glass	Plastic Systems	Moulded Glass	Life Science Research	Head office	Group
Segment sales	**Q1–Q3 09**	225.0	238.4	224.9	66.0	0.0	754.3
	Q1–Q3 08	221.3	258.6	246.9	67.3	0.0	794.1
Thereof intragroup sales	**Q1–Q3 09**	-9.6	0.0	-0.3	-0.1	0.0	-10.0
	Q1–Q3 08	-9.4	0.0	-1.3	0.0	0.0	-10.7
Sales third parties	**Q1–Q3 09**	215.4	238.4	224.6	65.9	0.0	744.3
	Q1–Q3 08	211.9	258.6	245.6	67.3	0.0	783.4
Share of profit/loss of associated compnies	**Q1–Q3 09**	0.0	0.0	0.0	0.0	0.0	0.0
	Q1–Q3 08	0.0	0.0	0.2	0.0	0.0	0.2
Adjusted EBITDA	**Q1–Q3 09**	53.2	47.5	35.4	6.1	-14.4	127.8
	Q1–Q3 08	54.2	47.4	52.0	8.0	-14.7	146.9
Depreciation and amortization	**Q1–Q3 09**	-19.5	-13.1	-21.2	-2.0	-0.1	-55.9
	Q1–Q3 08	-17.1	-15.5	-19.7	-1.7	0.0	-54.0
Adjusted EBITA	**Q1–Q3 09**	33.7	34.4	14.2	4.1	-14.5	71.9
	Q1–Q3 08	37.1	31.9	32.3	6.3	-14.7	92.9
Amortization of fair value adjustments	**Q1–Q3 09**	-3.3	-18.5	-2.9	-1.3	-2.6	-28.6
	Q1–Q3 08	-3.2	-18.7	-3.0	-1.3	-2.6	-28.8
Adjusted EBIT	**Q1–Q3 09**	30.4	15.9	11.3	2.8	-17.1	43.3
	Q1–Q3 08	33.9	13.2	29.3	5.0	-17.3	64.1
Restructuring/one-off expenses and income	**Q1–Q3 09**	-0.9	-2.5	-1.0	-0.3	0.6	-4.1
	Q1–Q3 08	-2.3	-0.1	-1.0	-0.5	-0.1	-4.0
Impairment loss	**Q1–Q3 09**	0.0	-5.3	0.0	0.0	0.0	-5.3
	Q1–Q3 08	0.0	-37.6	0.0	0.0	0.0	-37.6
Result from operations	**Q1–Q3 09**	29.5	8.1	10.3	2.5	-16.5	33.9
	Q1–Q3 08	31.6	-24.5	28.3	4.5	-17.4	22.5
Financial result	**Q1–Q3 09**	-12.3	-4.8	-2.1	0.0	-11.4	-30.6
	Q1–Q3 08	-12.5	-4.3	-2.4	0.0	-11.2	-30.4
Consolidated profit or loss before income taxes	**Q1–Q3 09**	–	–	–	–	–	3.3
	Q1–Q3 08	–	–	–	–	–	-7.9
Income taxes	**Q1–Q3 09**	–	–	–	–	–	-7.4
	Q1–Q3 08	–	–	–	–	–	-6.8
Consolidated profit or loss for the period	**Q1–Q3 09**	–	–	–	–	–	-4.1
	Q1–Q3 08	–	–	–	–	–	-14.7

Transfer prices between the segments are based on customary market terms on an arm's-length basis.

(12) Related-party disclosures (IAS 24)

In the course of our business operations we have business relations to companies which are connected to members of the Supervisory Board of Gerresheimer AG. This business results mainly from trade and service relationships conducted on the basis of normal market prices and conditions, and totalled EUR 4.7m in the first nine months of 2009.

Until April 18, 2008 related parties of the Gerresheimer Group included BCP Murano II S.à.r.l., Luxembourg, an indirect subsidiary of Blackstone Capital Partners IV, Cayman Islands. Before its IPO in June 2007, Gerresheimer AG was a direct subsidiary of BCP Murano II S.à.r.l., Luxembourg. In the course of the IPO of Gerresheimer AG, BCP Murano II S.à.r.l. surrendered shares from its holding in Gerresheimer AG with the result that the shareholding of BCP Murano II S.à.r.l. in Gerresheimer AG fell to 24.96 %. On April 18, 2008 BCP Murano II S.à.r.l. sold its entire holding in Gerresheimer AG to various institutional investors.

In the financial year 2008, there were no service relationships or financing transactions with the companies of the Blackstone Group.

(13) Events after the balance sheet date

No events of material importance for the net assets, financial position and results of operation of the Gerresheimer Group occurred after August 31, 2009.

The Management Board released the quarterly consolidated financial statements after discussion with the examination board of the audit committee on October 14, 2009.

Financial Calendar

February 10, 2010	Annual Report 2009
April 14, 2010	Interim Report 1st Quarter 2010
April 29, 2010	Annual General Meeting in Düsseldorf
July 14, 2010	Interim Report 2nd Quarter 2010
October 6, 2010	Interim Report 3rd Quarter 2010

Imprint

Publisher

Gerresheimer AG
Benrather Strasse 18-20
40213 Düsseldorf
Germany
Phone +49 211 6181-00
Fax +49 211 6181-295
E-mail info@gerresheimer.com
www.gerresheimer.com

Concept and Layout

HGB Hamburger Geschäftsberichte GmbH & Co. KG, Hamburg

Text

Gerresheimer AG, Düsseldorf

Note to the Interim Report
This Interim Report is the English translation of the original German version; in case of deviations between these two the German version prevails.

Note regarding the rounding of figures
Due to the commercial rounding of figures and percentages small deviations may occur.

Disclaimer
This Interim Report contains certain future-oriented statements. Future-oriented statements include all statements which do not relate to historical facts and events and contain future-oriented expressions such as "believe", "estimate", "assume", "expect", "forecast", "intend", "could" or "should" or expressions of a similar kind. Such future-oriented statements are subject to risks and uncertainties since they relate to future events and are based on the Company's current assumptions, which may not in the future take place or be fulfilled as expected. The Company points out that such future-oriented statements provide no guarantee for the future and that actual events including the financial position and profitability of the Gerresheimer Group and developments in the economic and regulatory fundamentals may vary substantially (particularly on the down side) from those explicitly or implicitly assumed or described in these statements. Even if the actual results for the Gerresheimer Group, including its financial position and profitability and the economic and regulatory fundamentals, are in accordance with such future-oriented statements in this Interim Report, no guarantee can be given that this will continue to be the case in the future.

Gerresheimer AG

Benrather Strasse 18-20
40213 Düsseldorf
Germany
Phone +49 211 6181-00
Fax +49 211 6181-295
E-mail info@gerresheimer.com
www.gerresheimer.com